These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17378147)

  • 21. Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern.
    Chung SH; Heimbürger O; Lindholm B
    Semin Dial; 2008; 21(1):7-10. PubMed ID: 18251948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of glycerol-containing peritoneal dialysis fluid on peritoneal macrophage function in vivo.
    de Fijter CW; Verbrugh HA; Oe PL; Peters ED; van der Meulen J; Donker AJ; Verhoef J; Lameire N
    Adv Perit Dial; 1991; 7():154-7. PubMed ID: 1680414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Inflammation in peritoneal dialysis].
    Ryckelynck JP; Lobbedez T; Pujo M; el Haggan W; Hurault de Ligny B
    Nephrologie; 2003; 24(7):367-70. PubMed ID: 14650748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maltose, a promising osmotic agent in peritoneal dialysis solution.
    Shu ZJ; Peng YM; Sun L; Xiao L; Liu YH; Li J; Ling GH; Tang WB; Halmurat U; Liu FY
    Med Hypotheses; 2010 Dec; 75(6):645-7. PubMed ID: 20801582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fate of the glucose degradation products 3-deoxyglucosone and glyoxal during peritoneal dialysis.
    Tauer A; Bender TO; Fleischmann EH; Niwa T; Jörres A; Pischetsrieder M
    Mol Nutr Food Res; 2005 Jul; 49(7):710-5. PubMed ID: 15915443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New technologies in peritoneal dialysis.
    Bargman JM
    Clin J Am Soc Nephrol; 2007 May; 2(3):576-80. PubMed ID: 17699465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic and local impact of glucose and glucose degradation products in peritoneal dialysis solution.
    Kim YL; Cho JH; Choi JY; Kim CD; Park SH
    J Ren Nutr; 2013 May; 23(3):218-22. PubMed ID: 23510669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protecting the peritoneal membrane in dialyzed patients.
    Grzegorzewska AE
    Adv Med Sci; 2006; 51():191-6. PubMed ID: 17357307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Which dialysis method should be proposed to type 2 diabetics?].
    Ryckelynck JP
    Nephrologie; 2000; 21(4):161-2. PubMed ID: 10976430
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetics on dialysis in Italy: a nationwide epidemiological study.
    Panzetta G; Basile C; Santoro A; Ancarani E; Costantini S; Guarnieri F; Verzetti G
    Nephrol Dial Transplant; 2008 Dec; 23(12):3988-95. PubMed ID: 18658176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis.
    Szeto CC; Johnson DW
    Semin Nephrol; 2017 Jan; 37(1):30-42. PubMed ID: 28153193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammation in peritoneal dialysis.
    Lai KN; Leung JC
    Nephron Clin Pract; 2010; 116(1):c11-8. PubMed ID: 20460934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and quantification of the glucose degradation product glucosone in peritoneal dialysis fluids by HPLC/DAD/MSMS.
    Mittelmaier S; Fünfrocken M; Fenn D; Fichert T; Pischetsrieder M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Apr; 878(11-12):877-82. PubMed ID: 20189892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of pH-neutral peritoneal dialysis fluids on adipokine secretion from cultured adipocytes.
    Teta D; Maillard M; Tedjani A; Passlick-Deetjen J; Burnier M
    Nephrol Dial Transplant; 2007 Mar; 22(3):862-9. PubMed ID: 17132702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biocompatibility of peritoneal dialysis fluids].
    Boulanger E; Moranne O; Wautier MP; Rougier JP; Ronco P; Pagniez D; Wautier JL
    Nephrol Ther; 2005 Mar; 1(1):14-22. PubMed ID: 16895663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis.
    La Milia V; Limardo M; Cavalli A; Crepaldi M; Locatelli F
    Nephrol Dial Transplant; 2009 Sep; 24(9):2894-8. PubMed ID: 19349295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citrate supplementation of PD fluid: effects on net ultrafiltration and clearance of small solutes in single dwells.
    Braide M; Haraldsson B; Persson U
    Nephrol Dial Transplant; 2009 Jan; 24(1):286-92. PubMed ID: 18796439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal dialysis in diabetic patients.
    Lee HB; Chung SH; Chu WS; Kim JK; Ha H
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S200-3. PubMed ID: 11576955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing the formation of glucose degradation products in peritoneal dialysis solutions by ultrahigh temperature ohmic heating.
    Shapira A; Shazman A; Ungar Y; Shimoni E
    Mol Nutr Food Res; 2007 Apr; 51(4):473-8. PubMed ID: 17390399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early initiation of peritoneal dialysis in diabetic patients.
    Coronel F; Cigarran S; Herrero JA
    Scand J Urol Nephrol; 2009; 43(2):148-53. PubMed ID: 19085460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.